The Summary
In a 24-month randomized controlled trial, researchers evaluated whether 2 grams daily of docosahexaenoic acid (DHA) could benefit 365 older adults with low omega-3 intake and elevated dementia risk. Results showed a significant increase in the DHA-to-arachidonic acid ratio in the cerebrospinal fluid of the treatment group after six months, proving the supplement successfully reached the central nervous system regardless of APOE ε4 genetic status. However, this biochemical boost did not lead to any measurable improvements in brain volume or cognitive performance over the two-year study period.
Why this is interesting
For years, scientists believed increasing omega-3 intake could ward off dementia, especially in genetically vulnerable individuals. This study confirms that high-dose DHA supplements successfully cross the blood-brain barrier. However, the lack of cognitive or structural brain benefits over two years suggests that simply flooding the brain with DHA isn't enough to stop cognitive decline once risk factors are established. For readers, this highlights that supplements are not a quick fix for brain aging, and future research must focus on how the brain actually metabolizes these fatty acids.